In Women Whose Breast Cancer Has Spread, Study Compares Standard Against Newer Treatm

[News]

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. This study was presented by Peter A. Kaufman, M.D...

More...

[ElaineM]

Good information !!